Kalaris Therapeutics, Inc. reported improved Q3'25 results, with a net loss of $11.9M and $77M in cash. Click here to read why KLRS stock is a Buy.
New research has mapped the cell types that specialize to form reproductive organs in both sexes, identifying key genes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback